List view / Grid view

Articles

Kick-starting the immune response – the shifting landscape of immuno-oncology

29 March 2019 | By Cisbio Bioassays, Nathan Robertson

The landscape of cancer treatment has changed dramatically in the last seven years, beginning with the approval of Ipilmumab in 2011, the first immunotherapy drug. Efforts to unsheathe the tumour cells of their protective microenvironment and expose them to an active immune response have delivered several monoclonal antibodies (mAbs) that…

The importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays

21 March 2019 | By Massimiliano Runfola - University of Pisa - Italy, Sheraz Gul - Fraunhofer IME - Germany

Over the past 30 years, one strategy the pharmaceutical industry has adopted in the drug discovery process has been to “fail early, fail often”.1,2 As most molecules in the early stages of drug discovery will have sub-optimal characteristics, significant modification is necessary to improve their properties.

Drug discovery from the age of information to the age of intelligence

20 March 2019 | By Jeff Martin (Head of Compound Management - Alkermes Inc.)

Data drives drug discovery, yet it continues to be among the biggest challenges faced by the industry.1 Experiments are often not repeatable and data interpretation is subject to the biases and limitations of human beings.

Cell line development – global market drivers, trends and its impact on improving biologics development from early phase to IND during the drug discovery process

19 March 2019 | By Aparajita Dubey - Associate Consultant at Prescient Healthcare Group

Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. This stage involves the production of recombinant proteins such as monoclonal antibodies,…

Lab Automation In-Depth Focus 2019

18 March 2019 | By Drug Target Review

In this In-Depth Focus: realising the promise of laboratory automation in biomedical research, drug discovery from the age of information to the age of intelligence, and transforming drug discovery, development and delivery with flow chemistry.

Informatics In-Depth Focus 2019

15 March 2019 | By Drug Target Review

In this In-Depth Focus: AI-driven automated chemistry as a tool to accelerate drug discovery, and a look at network-driven drug discovery

Assays In-Depth Focus 2019

14 March 2019 | By Drug Target Review

In this In-Depth Focus: the importance of characterising chemical starting points of drugs using appropriate in vitro ADME-toxicity assays, and why do we have no effective treatments for osteoarthritis?

Drug Target Review – Issue 1 2019

14 March 2019 | By Drug Target Review

In this issue: AI-driven automated chemistry as a tool to accelerate drug discovery processes, the shifting landscape of immuno-oncology, and how lipid molecules provide an insight into biological research.

Network-driven drug discovery

14 March 2019 | By Alan Whitmore - e-therapeutics Plc, Jonny Wray - e-therapeutics Plc

Target-driven drug discovery, in which the starting point is a specific protein target hypothesised to play an important role in disease, has been the dominant paradigm for the last few decades. However, phenotypic-driven drug discovery, which does not rely on a specific target hypothesis, is starting to regain traction for…

Hit-to-lead discovery at a nonprofit research institute

7 February 2019 | By Anthony Pinkerton

Small molecule drug discovery has long been the domain of pharmaceutical companies, and that’s not likely to change anytime soon. But there’s a cadre of universities and nonprofit research institutes that have embraced drug development at its earliest stages, in some cases identifying and optimising compounds that target possible disease-driving…

Small molecules could have big benefits in the battle against cancers

15 January 2019 | By Douglas J. Swirsky

Immunotherapy and targeted treatments, including targeted chemotherapy, continue to show great potential in cancer care. Future steps in their development will involve improving their ability to treat a wider range of cancers and a broader cross-section of the patient population, especially those for whom current treatments have shown limited efficacy...

Beyond ‘simple’ biology – turning organoids, spheroids, and 3D tissue models into physiologically relevant high-content assays for drug discovery

11 December 2018 | By Matthias Nees and Malin Åkerfelt (University of Turku - Finland)

Drug discovery is still hampered by the routine use of cell-based models that often fail to recapitulate the truly relevant biological complexity of the corresponding disease. Just moving from two- (2D) towards three-dimensional (3D) cell culture model systems like spheroids and organoids is not enough to generate truly representative and…

New frontiers in G protein-coupled receptor drug discovery

10 December 2018 | By Christopher J. Langmead

G protein-coupled receptors (GPCRs) are seven transmembrane spanning proteins that mediate the physiological responses to a broad array of stimuli, including photons, biogenic amines, peptides and large proteins. They represent the target of approximately one-third of all approved drugs,1 yet paradoxically remain a relatively under-exploited protein class.

Proteomics: cracking the molecular mystery of diseases and therapeutics

10 December 2018 | By Anowarul Amin

In the wake of the human genome project, molecular biology and genetic technologies are tremendously integrating into biomedical research. Currently, PCR, qPCR, and sequencing are key tools in the clinical laboratory for the detection and characterisation of microorganisms and genetic disorders.

Webinar highlights: Integrated fragment based approach reveals enzymatic inhibitors with potential therapeutic application

10 December 2018 | By NanoTemper Technologies

This webinar, held on 25 October 2018, presented the results from integrated fragment-based approaches for Indoleamine 2,3 dioxygenase 1 (IDO1), an enzyme widely recognised as a drug target for the development of immunotherapeutic small molecules in oncology, unveiling the first ligands able to modulate non-catalytic signalling.

Page 26 of 51
<
1
...
21
22
23
24
25
26
27
28
29
30
...
51
>

Cookie	Type	Duration	Description
cookielawinfo-checkbox-advertising-targeting	persistent	1 year	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics	persistent	1 year	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary	persistent	1 year	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	persistent	1 year	This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID	session	1 year	This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy	persistent	1 year	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged	session	1 year	This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.

Cookie	Type	Duration	Description
advanced_ads_browser_width	persistent	1 month	This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions	persistent	2 years	This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info	persistent	1 month	This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer	persistent	1 year	This cookie is set by Advanced Ads and sets the referrer URL.
bscookie	persistent	2 years	This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE	persistent	2 years	This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr	persistent	3 months	This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory	persistent	1 month	This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE	persistent	5 months	This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.

Cookie	Type	Duration	Description
bcookie	persistent	2 years	This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS	persistent	30 minutes	This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang	session	1 year	This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc	persistent	1 day	This cookie is set by LinkedIn and used for routing.
lissc	persistent	11 months	This cookie is set by LinkedIn share Buttons and ad tags.
vuid	persistent	2 years	We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId	persistent	2 years	This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule	persistent	20 minutes	This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session	persistent	20 minutes	This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues	persistent	20 minutes	This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga	persistent	2 years	This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat	persistent	1 minute	This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid	persistent	1 day	This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.

Cookie	Type	Duration	Description
cf_ob_info	persistent	1 minute	This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob	persistent	1 minute	This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only	session	1 year	This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush	persistent	1 month	This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db	persistent	Until cleared	This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC	session	1 year	This cookie is set by Youtube and is used to track the views of embedded videos.

Recommended

Articles